Objective-Emerging evidence suggests that methionine oxidation can directly affect protein function and may be linked to cardiovascular disease. The objective of this study was to define the role of the methionine sulfoxide reductase A (MsrA) in models of vascular disease and identify its signaling pathways. Approach and Results-MsrA was readily identified in all layers of the vascular wall in human and murine arteries. Deletion of the MsrA gene did not affect atherosclerotic lesion area in apolipoprotein E-deficient mice and had no significant effect on susceptibility to experimental thrombosis after photochemical injury. In contrast, the neointimal area after vascular injury caused by complete ligation of the common carotid artery was significantly greater in MsrA-deficient than in control mice. In aortic vascular smooth muscle cells lacking MsrA, cell proliferation was significantly increased because of accelerated G 1 /S transition. In parallel, cyclin D1 protein and cdk4/cyclin D1 complex formation and activity were increased in MsrA-deficient vascular smooth muscle cell, leading to enhanced retinoblastoma protein phosphorylation and transcription of E2F. Finally, MsrA-deficient vascular smooth muscle cell exhibited greater activation of extracellular signal-regulated kinase 1/2 that was caused by increased activity of the Ras/Raf/mitogen-activated protein kinase signaling pathway. 
M ethionine sulfoxide reductases (Msrs) are evolutionarily conserved and ubiquitously expressed antioxidant enzymes that repair oxidized proteins by thioredoxin-dependent reduction of methionine sulfoxide residues. The cyclic oxidation-reduction of methionine residues has been proposed to be an antioxidant defense mechanism whereby oxidation of methionine serves as a sink for excess cellular reactive oxygen species. 1 More recently, limited examples have emerged that methionine oxidation alters the function of specific proteins, including calmodulin, 2 the calcium-and calmodulin-dependent kinase II 3 and potassium channels. 4 Methionine oxidation also has been observed to contribute to the redox regulation of several vascular proteins involved in thrombosis and atherosclerosis. 5 These observations suggest that Msr may control specific signaling pathways via the regulation of protein methionine oxidation and reduction. However, despite the well-established role of oxidative stress in vascular diseases such as atherosclerosis, thrombosis, and neointimal hyperplasia after mechanical injury, 6 the distinct vascular phenotypes and signaling pathways affected by methionine oxidation in vivo have remained poorly defined.
The mammalian Msr system consists of 2 classes of proteins: MsrA and MsrB. MsrA is present in the nucleus, cytoplasm, and mitochondria in multiple cell types, including vascular smooth muscle cells (VSMCs), 7 and preferentially reduces the S-enantiomer of methionine sulfoxide. In contrast, MsrB comprises a class of 3 isoforms that preferentially reduce the R-enantiomer of peptide-associated methionine sulfoxide, 8 suggesting distinct roles for the 2 classes of Msr.
MsrA function has been studied in the context of aging and age-related neurodegenerative diseases, such as Alzheimer and Parkinson diseases. 9, 10 In the cardiovascular system, MsrA function has mainly been investigated in myocardial disease models that are characterized by high levels of oxidative stress. In particular, MsrA protects cardiomyocytes from hypoxia/reoxygenation injury in vitro, and MsrA limits myocardial infarct size after ischemia/reperfusion injury of the heart ex vivo. 11, 12 Myocardial-specific overexpression of MsrA in mice protects against wall rupture after myocardial infarction, 13 whereas MsrA-deficient (MsrA −/− ) mice display increased myocardial apoptosis, reduced survival, and impaired left ventricular ejection fraction. 3 In contrast, the role of MsrA in reactive oxygen species-dependent vascular disease remains less understood. Interestingly, 2 independent genome-wide association studies in humans have identified a polymorphism in intron 2 of the human MsrA gene that correlates with increased ischemic cardiovascular disease although mechanistic insight is lacking. 14, 15 Identification of the protein substrates of MsrA by systematic approaches has been hampered by the lack of specific tools to identify oxidized methionine residues in proteins. [16] [17] [18] In addition, conventional sample preparation necessary for proteomic approaches may introduce artificial modifications because of the exquisite susceptibility of methionine residues to oxidation. For these reasons, only a few studies have applied a systematic proteomics-based approach to identify cellular proteins that are modified by methionine oxidation under conditions of increased oxidative stress. 19, 20 There is limited agreement between the studies in terms of identified protein targets of methionine oxidation. Moreover, in most cases, it remains unclear whether these modifications affect protein function. The alternative approach of treating cells with oxidants such as chloramine, which preferentially oxidizes methionine residues, has yielded a list of candidate target proteins with altered function. Examples with potential relevance to vascular disease include apolipoproteins, the extracellular matrix protein fibronectin 21 and the actin-binding protein cofilin, 22 which regulates VSMC migration and neointimal formation. 23 However, it is unclear whether methionine modifications of these proteins occur under physiological or pathological conditions in vivo.
In this study, we applied an alternative strategy to define the in vivo contribution of MsrA to ischemic cardiovascular disease. In particular, we studied the impact of MsrA deletion in murine models of atherosclerosis, thrombosis, and mechanical injury, recapitulated relevant phenotypes in vitro and identified underlying signaling pathways.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Deficiency of MsrA Does Not Alter Susceptibility to Experimental Thrombosis or Vascular Lesion Area in Atherosclerotic Mice
We first evaluated the expression of MsrA by immunofluorescence in nonatherosclerotic and atherosclerotic human coronary arteries. MsrA protein was distributed throughout the arterial wall in nonatherosclerotic samples. In the atherosclerotic plaque, MsrA was robustly expressed and most prominent in VSMC that were identified by colabeling for α-smooth muscle actin ( Figure 1A) .
Because of its presence in atherosclerotic plaques, we hypothesized that deletion of MsrA increases atherosclerotic plaque formation. Thus, MsrA −/− mice were crossed with apolipoprotein E-deficient (ApoE −/− ) mice and fed either a control diet or a Western diet to induce atherosclerosis. Total cholesterol levels were significantly increased by the Western diet when compared with the control diet regardless of genotype ( Figure 1B) . Similarly, high-density lipoprotein (HDL) and low-density lipoprotein subfractions were not different between genotypes ( Figure IA in the online-only Data Supplement). The Western diet significantly increased the cross-sectional atherosclerotic lesion area in the aortic sinus and the en face lesion area of the entire aorta when compared with the control diet ( Figure 1C-1F) . Deficiency of MsrA did not significantly increase lesion area in ApoE −/− mice fed either the control diet or the Western diet. No differences in the number of macrophages in atherosclerotic plaque were detected between genotypes ( Figure IB and IC in the onlineonly Data Supplement).
Ischemic cardiovascular mortality is frequently caused by acute thrombosis at the site of an atherosclerotic lesion. Thus, we also examined whether MsrA deficiency alters the susceptibility to experimental thrombosis of the carotid artery induced by photochemical injury. As expected, mice fed the Western diet had shorter times to first occlusion and stable occlusion than mice fed the control diet ( Figure 1G and 1H) Previous data have suggested that inactivation of thrombomodulin by methionine oxidation results in decreased generation of the anticoagulant activated protein C (APC) in vitro. 24 Therefore, we measured plasma levels of APC after infusion of thrombin. Plasma APC levels were similar in MsrA ) vessel segments, we observed robust MsrA staining in the neointima 14 days after carotid ligation ( . C and D, Quantification and representative images of percent lesion area (Oil red O area/total area; n=8-11 per group). Scale bar, 500 μm. E and F, Representative images and quantification of atherosclerotic lesion area in aortic sinus. G, Time to first occlusion and (H) stable occlusion of the carotid artery after photochemical injury (n=7-13). I, Activated protein C levels (APC) after thrombin infusion (n=6-9). I indicates intima; and M, media. *P<0.05 compared with control diet. using 3H-thymidine uptake assays, which showed an increase in DNA synthesis, a surrogate marker of proliferation ( Figure  3D ). This was confirmed by a significant increase in the proliferation rate of MsrA −/− when compared with that of MsrA +/+ VSMC grown in the presence of 10% serum ( Figure 3E ). Given the pronounced increase in proliferation of MsrA −/− VSMC, we next examined the impact of MsrA deficiency on cell cycle progression. After synchronization in serum-free media for 48 hours, MsrA −/− and MsrA +/+ VSMC were stimulated with 10% serum and the cell cycle profile was determined 6 and 24 hours later by flow cytometry. MsrA −/− VSMC re-entered the cell cycle faster after cell cycle arrest, with significantly more cells in S-phase and fewer cells in G 0 /G 1 phase than MsrA +/+ VSMC 24 hours after release ( Figure 3F and 3G). These data suggest a role for MsrA in cell cycle progression.
Because VSMC adhesion and migration contribute to the accumulation of VSMC in the neointima, we also evaluated whether MsrA deficiency impacts VSMC migration using Boyden chamber assays. We found that MsrA −/− VSMC had a 1.4-fold increase in migration when compared with MsrA These data indicate the MsrA deletion has a modest effect on migration and impairs cell adhesion. Because these findings are unlikely to explain the large increase in neointimal size, we concentrated on the mechanisms by which MsrA deletion increases VSMC proliferation.
Deletion of MsrA Increases Cell Cycle Progression Through Post-transcriptional Control of Cyclin D1
On the basis of data in Figure 3E that MsrA deletion accelerates progression through the cell cycle, we next evaluated protein levels of G 0 /G 1 cell cycle regulators. In MsrA −/− VSMC, cyclin D1, cyclin E, cyclin-dependent kinase (CDK) 2 were all significantly upregulated when compared with MsrA +/+ VSMC ( Figure 4A ). We also found that p21, which is traditionally considered a cell cycle inhibitor, 25, 26 was upregulated in MsrA −/− when compared with MsrA +/+ VSMC ( Figure 4A ). These data are consistent with recent publications indicating that p21 is required for cell proliferation through stabilization of the cyclin D/CDK4 complex. [27] [28] [29] We also examined whether MsrA deficiency alters mRNA levels of cyclin D, the most upstream regulator of cell cycle progression. Quantitative realtime-polymerase chain reaction demonstrated that, in contrast to protein expression, cyclin D1 mRNA levels were decreased rather than increased in MsrA −/− VSMC ( Figure 4B ). Cyclin D2 and D3 mRNA levels were similar between genotypes. Cyclin D1 protein expression was increased in growth-arrested cells and 24 hours after release from growth arrest ( Figure 4C ). These data suggest that MsrA post-transcriptionally regulates cyclin D1 expression.
Cyclin D and CDK4 form a complex to phosphorylate and activate retinoblastoma protein (Rb), leading to cellular proliferation. 30 To examine whether MsrA −/− VSMC have increased cyclin D1/CDK4 complex formation, CDK4 was immunoprecipitated from VSMC lysates and the amount of bound cyclin D1 determined by Western blotting. We detected an increase in the cyclin D1/CDK4 complex in MsrA −/− when compared with MsrA +/+ VSMC ( Figure 5A ). Moreover, phospho-Rb levels were significantly elevated in MsrA −/− when compared with MsrA +/+ VSMC ( Figure 5B ). These findings were confirmed using a radioactive in vitro cyclin D/CDK4 activity assay, in which MsrA −/− VSMC displayed an increase in phosphorylation of Rb ( Figure 5C ). It is well established that Rb binds the E2F family of transcription factors, repressing their activation. 31 On phosphorylation of Rb, E2Fs are released and transcription of many genes is activated, including E2F isoforms. Analysis of mRNA levels of E2F1, E2F2, and E2F3 in activity in VSMC. In VSMC grown in 10% FBS, phosphorylation of ERK1/2 and its activating pathway was enhanced in MsrA −/− VSMC when compared with MsrA +/+ VSMC ( Figure  6A ). Increased ERK1/2 activity in MsrA −/− VSMC was confirmed by ELISA for phospho-ERK1/2 ( Figure 6B ). Next, we serum-deprived VSMC followed by short-term treatment with 10% FBS and assessment of ERK1/2 activation. When compared with untreated control, ERK1/2 phosphorylation was increased in response to serum regardless of genotype ( Figure 6C) . However, the magnitude of the effect was more pronounced under MsrA deficiency. We also examined activation of Akt because a previous study in breast cancer cells demonstrated that MsrA knockdown reduces protein levels of phosphatase and tensin homolog (PTEN), the negative master regulator of Akt. 32 However, we did not detect changes in PTEN expression or Akt activation in MsrA −/− VSMC when compared with MsrA +/+ VSMC ( Figure V in the online-only Data Supplement).
To hone in on the mechanism by which MsrA deletion results in increased ERK1/2 phosphorylation, we assessed activation of the upstream regulators of ERK1/2, c-rapidly accelerated fibrosarcoma (c-Raf), and mitogen-activated protein kinase (MEK). When compared with MsrA +/+ VSMC, phosphorylation of MEK and c-Raf was increased in MsrA −/− ( Figure 6A ). In addition, MsrA-deficient VSMC displayed an increase in the levels of activated Ras when compared with MsrA +/+ VSMC ( Figure 6D ). To confirm that enhanced ERK activation in MsrA −/− VSMC is through MEK, cells were treated with the MEK inhibitor U0126. As expected, phospho-ERK1/2 was decreased by treatment with 10 μmol/L U0126 for 16 hours in both MsrA +/+ and MsrA −/− VSMC when compared with vehicle control ( Figure 6E ). Activation of ERK1/2 promotes cell cycle progression, in part, through upregulation of cyclin D1.
33,34 Therefore, we examined protein levels of cyclin D1 after MEK inhibition. When compared with MsrA +/+ VSMC, cyclin D1 protein levels were significantly decreased in MsrA −/− VSMC in response to MEK inhibition with U0126 ( Figure 6E ). To directly investigate the mechanistic effect of MsrA on the proposed pathway, we overexpressed MsrA in MsrA +/+ and MsrA −/− VSMC to determine its effect on cyclin D1 levels. When compared with MsrA −/− expressing control adenovirus, cyclin D1 levels and ERK1/2 phosphorylation were markedly lower with overexpression of MsrA ( Figure 6F and 6G). Collectively, these data implicate MsrA in ERK1/2-dependent cyclin D1 regulation.
Discussion
Here, we evaluated the role of MsrA in vascular pathology. MsrA was expressed in all layers of the arterial wall of humans and mice, with high levels in VSMC. MsrA deficiency experiments in cultured VSMC revealed amplified cyclin D1 protein levels, cyclin D1/cdk4 complex formation, Rb phosphorylation, and increased E2F transcription. MsrA deletion increased activation of the Ras/Raf/MEK/ERK1/2 pathway, resulting in elevated cyclin D1 protein levels. Taken together, these data identify methionine oxidation as a key event in regulation of specific VSMC signaling pathways that mediate the vascular response to injury. MsrA protein levels are downregulated in many types of human cancer in which cellular proliferation is increased, including leukemia and lymphoma cell lines and hepatocellular, breast, and colon tumors. 32, 35, 36 In these studies, MsrA deficiency correlated with more aggressive and invasive growth and advanced tumor grade. 32, 36 However, the signaling pathways by which MsrA downregulation mediates enhanced proliferation in malignant growth have not been conclusively identified. In one study that reported increased proliferation in breast cancer cells after knockdown of MsrA, protein levels of PTEN, a lipid phosphatase that antagonizes phosphatidylinositol-3-kinase signaling, were decreased. 32 In support of a mechanistic role for phosphatidylinositol-3-kinase, treatment with a phosphatidylinositol-3-kinase inhibitor blocked proliferation. Numerous studies have mechanistically implicated Akt in VSMC proliferation. [37] [38] [39] [40] Thus, we tested the hypothesis that Akt-dependent signaling is elevated in MsrA −/− VSMC. Unexpectedly, we did not detect a difference in PTEN expression or Akt signaling after deletion of MsrA. However, we found a significant increase in activation of ERK1/2, which has also been implicated in neointimal proliferation after mechanical vascular injury. 41 These data are consistent with a recent study linking MsrA overexpression to inhibition of ERK1/2 in microglia. 42 Together, these data support a role of MsrA in malignant and nonmalignant cell proliferation.
Numerous previous reports have established that activation of Ras/MEK/ERK1/2 induces cyclin D, 43 with the bulk of the studies identifying transcriptional regulation of cyclin D as a key driving mechanism. In our experiments, we detected increased cyclin D1 protein but not mRNA levels in MsrA −/− VSMC, and MEK inhibition restored cyclin D1 to MsrA +/+ levels. There is evidence that MEK1/ERK1/2 can regulate cyclin D post-transcriptionally, through promotion of the nucleocytoplasmic export of its mRNAs [44] [45] [46] or through increased cyclin D1/Cdk4 complex assembly. 47 ERK can also phosphorylate and activate p53, leading to cell cycle arrest. 48 However, p53 stability is negatively regulated by methionine oxidation, 49 thus deletion of MsrA may activate ERK but decrease p53 levels.
As the most upstream regulator of the proposed signaling pathway, we interrogated activation of the single-subunit small GTPase Ras. Ras mediates growth factor-dependent cell proliferation and differentiation. 50 Consistently, the inhibition of Ras or its multiple regulators decreases neointimal proliferation after vascular injury. [51] [52] [53] [54] Ras activity is modulated directly by redox regulation of cysteine residues, as demonstrated for the conserved phosphoryl-binding loop or a nucleotidebinding domain at Cys 118. 55 However, there are presently no data to implicate methionine modifications in modulating the activity of Ras or its binding partners. Alternatively, MsrA may promote the recruitment of Ras to the plasma membrane and thereby affect its activity as proposed in a recent study on MsrB1 regulation of the transient receptor potential melastatin type 6 transient receptor potential ion channel. 56 Finally, multiple guanine nucleotide exchange factors and GTPaseactivating proteins (GAPs) may be activated by methionine oxidation, a hypothesis that requires further in-depth investigation. Because Ras activation is a driver of accelerated proliferation in malignant diseases that are also characterized by lower MsrA activity, our data may provide further insight into MsrA function in other proliferative diseases.
In contrast to our findings in MsrA −/− VSMC, two earlier studies reported that acute knockdown of MsrA and MsrB3 in embryonic fibroblasts results in decreased cell proliferation. 57, 58 Of note, the rate of proliferation in the fibroblast studies was mainly examined by MTT assay, which depends on the cellular metabolic activity because of nicotinamide adenine dinucleotide phosphate flux. Because MsrA is expressed in both cytoplasm and the mitochondria in VSMC, 59 it may affect nicotinamide adenine dinucleotide phosphate flux, possibly independently from its role in proliferation. In fact, a proteomic analysis of 293T cells after MsrA knockdown revealed a subunit of nicotinamide adenine dinucleotide hydrogen dehydrogenase 1β as target of methionine oxidation. 20 For these reasons, we examined proliferation by cell counting, 3H-thymidine uptake, and cell cycle analysis, and found that all of these approaches confirmed increased proliferation of MsrA −/− VSMC. Another potential explanation for the discrepancy between our findings and the previous studies is that chronic MsrA deletion may induce alterations of the cellular redox state that affect cell proliferation, which may not be apparent with acute MsrA knockdown.
Because ischemic cardiovascular disease is typically caused by acute rupture of atherosclerotic plaque followed by thrombosis, we tested whether MsrA deletion affects the development of atherosclerotic lesions or the susceptibility to experimental thrombosis in murine models. Although corresponding in vivo studies are largely lacking, several recent in vitro studies have suggested that methionine oxidation may favor a prothrombotic state. 5 First, the neutrophil oxidant hypochlorous acid inhibited von Willebrand factor proteolysis by oxidizing von Willebrand factor at methionine 1606. 60 Second, exposure of the von Willebrand factor protease, a disintegrin and metalloproteinase with a thrombospondin type 1 motif 13, to hypochlorous acid induced methionine oxidation at several residues, 61 which was accompanied by reduced enzyme activity. Third, methionine oxidation of fibrinogen was associated with a dense network of fibrin, which likely inhibits plasminogen diffusion. 62 Finally, thrombomodulin in the membrane of endothelial cells is inactivated via oxidation of a key methionine residue under conditions of oxidative stress typical of vascular inflammation. 24 Thrombomodulin binds thrombin and changes its substrate specificity, allowing it to efficiently generate APC, an endogenous circulating protease that has both antithrombotic and anti-inflammatory properties. However, we did not detect any differences in atherosclerotic lesion area, APC generation, or susceptibility to arterial thrombosis between MsrA (Figure 1 ). These data suggest that methionine oxidation may not be a major mediator of atherosclerosis and thrombosis in vivo. Alternatively, it remains possible that MsrA is unable to reduce methionine sulfoxide residues in extracellular prothrombotic proteins because of its subcellular localization in the nucleus, cytoplasm, and mitochondria.
Likewise, in subjects with coronary artery disease, increased levels of methionine oxidation of apolipoprotein A-I correlate with disease severity. 63 Because the protein modification also leads to decreased ATP-binding cassette transporter A1-mediated cholesterol efflux from HDL, methionine oxidation is expected to enhance the severity of atherosclerosis. A study in methionine-induced hyperhomocysteinemia reported similar findings with altered HDL oxidation and the ability to efflux cholesterol from macrophages. 64 However, a direct proof of a causal relationship between methionine oxidation of HDL and atherosclerotic lesion size or instability is currently lacking. Of note, nearly all studies of HDL oxidation have been performed in vitro under oxidizing conditions that may not occur in vivo. An alternative explanation is that additional, unidentified antithrombotic or antiatherosclerotic pathways are simultaneously activated by methionine oxidation. Finally, murine disease models of thrombosis and atherosclerosis do not completely recapitulate the human pathology. Thus, based solely on the murine disease models examined, we cannot conclude that the protein targets that were identified in vitro studies do not impact human disease.
Our results provide compelling evidence that MsrA deficiency increases proliferation of VSMC and ERK1/2-mediated cyclin D1 regulation. This suggests that MsrA expression, or activation, which is known to protect proteins from oxidation and which acts as a reactive oxygen species scavenger, may protect against neointima formation. Although treatments with untargeted antioxidants have failed to reduce cardiovascular events, targeted activation of MsrA may provide a therapeutic benefit. Others have demonstrated increased MsrA activity with dietary supplements, selenium compounds, 65 and S-methyl-L-cysteine. 66 These compounds are potential therapeutics in the prevention of restenosis and should be further investigated.
